O. Al-khazrajy and A. Boxall, Risk-based prioritization of pharmaceuticals in the natural environment in Iraq, Environ Sci Pollut Res, vol.23, pp.15712-15726, 2016.

M. L. Amiel and M. C. Husson, The Theriaque database and information on side effects of drugs, Therapie, vol.49, pp.455-459, 1994.

Z. Banjac, A. Ginebreda, M. Kuzmanovic, R. Marcé, M. Nadal et al., Emission factor estimation of ca. 160 emerging organic microcontaminants by inverse modeling in a Mediterranean river basin, Sci Total Environ, vol.520, pp.241-252, 2015.

J. Barnett and G. M. Breakwell, The social amplification of risk and the hazard sequence: the October 1995 oral contraceptive pill scare, Health Risk Soc, vol.5, pp.301-313, 2003.

J. P. Besse, C. Kausch-barreto, and J. Garric, Exposure assessment of pharmaceuticals and their metabolites in the aquatic environment: application to the French situation and preliminary prioritization, Hum Ecol Risk Assess, vol.14, pp.665-695, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00454514

V. Booker, C. Halsall, N. Llewellyn, A. Johnson, and R. Williams, Prioritising anticancer drugs for environmental monitoring and risk assessment purposes, Sci Total Environ, vol.473, pp.159-170, 2014.

F. Bouder, Benefit/risk communication by the European Medicines Agency: a study of influential stakeholders' expectations and attitudes, 2011.

C. Carlsson, A. K. Johansson, G. Alvan, K. Bergman, and T. Kühler, Are pharmaceuticals potent environmental pollutants? Part I: Environmental risk assessments of selected active pharmaceutical ingredients, Sci Total Environ, vol.364, pp.67-87, 2006.

Y. Chartier, A. C. Johnson, and J. P. Sumpter, A rational approach to selecting and ranking some pharmaceuticals of concern for the aquatic environment and their relative importance compared with other chemicals, Environ Toxicol Chem, vol.35, pp.1021-1027, 2014.

E. Us, Exposure assessment tools and models. EPI Suite v4, vol.1, 2013.

, European Medicines Agency (EMA, 2006.

K. Fent, A. A. Weston, and D. Caminada, Ecotoxicology of human pharmaceuticals, Aquat Toxicol, vol.76, pp.122-159, 2006.

J. Fick, R. H. Lindberg, M. Tysklind, and D. Larsson, Predicted critical environmental concentrations for 500 pharmaceuticals, Regul Toxicol Pharmacol, vol.58, pp.516-523, 2010.

H. Franquet-griell, C. Gómez-canela, F. Ventura, and S. Lacorte, Predicting concentrations of cytostatic drugs in sewage effluents and surface waters of Catalonia (NE Spain), Environ Res, vol.138, pp.161-172, 2015.

X. García-santiago, A. Franco-uría, F. Omil, and J. M. Lema, Risk assessment of persistent pharmaceuticals in biosolids: dealing with uncertainty, J Hazard Mater, vol.302, pp.72-81, 2016.

R. Gaspar, J. Barnett, and B. Seibt, Crisis as seen by the individual: the norm deviation approach/La crisis vista por el individuo: el Enfoque de la Desviación de la Norma, Psyecology, vol.6, pp.103-135, 2015.

C. Gómez-canela, N. Cortés-francisco, X. Oliva, C. Pujol, F. Ventura et al., Occurrence of cyclophosphamide and epirubicin in wastewaters by direct injection analysis-liquid chromatography-high-resolution mass spectrometry, Environ Sci Pollut Res, vol.19, pp.3210-3218, 2012.

C. Gómez-canela, F. Ventura, J. Caixach, and S. Lacorte, Occurrence of cytostatic compounds in hospital effluents and wastewaters, determined by liquid chromatography coupled to high-resolution mass spectrometry, Anal Bioanal Chem, vol.406, pp.3801-3814, 2014.

M. Herrmann, O. Olsson, R. Fiehn, M. Herrel, and K. Kümmerer, The significance of different health institutions and their respective contributions of active pharmaceutical ingredients to wastewater, Environ Internat, vol.85, pp.61-76, 2015.

D. M. Kahan, Nanotechnology and society: the evolution of risk perceptions, Nat Nanotechnol, vol.4, pp.705-706, 2009.

V. Keller, R. J. Williams, C. Lofthouse, and A. C. Johnson, Worldwide estimation of river concentrations of any chemical originating from sewage-treatment plants using dilution factors, Environ Toxicol Chem, vol.33, pp.447-452, 2014.

K. Kümmerer, A. , and A. , Estimation of the cancer risk to humans resulting from the presence of cyclophosphamide and ifosfamide in surface water, Environ Sci Pollut Res, vol.17, pp.486-496, 2010.

K. H. Langford and K. V. Thomas, Determination of pharmaceutical compounds in hospital effluents and their contribution to wastewater treatment works, Environ Int, vol.35, pp.766-770, 2009.

S. Lichtenstein, P. Slovic, R. Naidu, V. Espana, Y. Liu et al., Emerging contaminants in the environment: risk-based analysis for better management, Chemosphere, vol.154, pp.350-357, 2006.

R. Oldenkamp, M. Huijbregts, A. Hollander, A. Versporten, H. Goossens et al., Spatially explicit prioritization of human antibiotics and antineoplastics in Europe, Environ Int, vol.51, pp.13-26, 2013.

M. Oosterhuis, F. Sacher, and T. L. Ter-laak, Prediction of concentration levels of metformin and other high consumption pharmaceuticals in wastewater and regional surface water based on sales data, Sci Total Environ, vol.442, pp.380-388, 2013.

S. Ortiz-de-garcía, P. Pinto, G. , G. Encina, P. et al., Consumption and occurrence of pharmaceutical and personal care products in the aquatic environment in Spain, Sci Total Environ, vol.444, pp.451-465, 2013.

N. Pidgeon, B. Harthorn, and T. Satterfield, Nanotechnology risk perceptions and communication: emerging technologies, emerging challenges, Risk Anal, vol.31, pp.1694-1700, 2011.

M. Rabiet, A. Togola, F. Brissaud, J. L. Seidel, H. Budzinski et al., Consequences of treated water recycling as regards pharmaceuticals and drugs in surface and ground waters of a mediumsized mediterranean catchment, Environ Sci Technol, vol.40, pp.5282-5288, 2006.
URL : https://hal.archives-ouvertes.fr/hal-01978614

F. Riva, E. Zuccato, and S. Castiglioni, Prioritization and analysis of pharmaceuticals for human use contaminating the aquatic ecosystem in Italy, J Pharm Biomed Anal, vol.106, pp.71-78, 2015.

L. Santos, M. Gros, S. Rodriguez-mozaz, C. Delerue-matos, A. Pena et al., Contribution of hospital effluents to the load of pharmaceuticals in urban wastewaters: identification of ecologically relevant pharmaceuticals, Sci Total Environ, vol.461, pp.302-316, 2013.

E. Touraud, B. Roig, J. P. Sumpter, and C. Coetsier, Drug residues and endocrine disruptors in drinking water: risk for humans?, Int J Hyg Environ Health, vol.214, pp.437-441, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00878471

C. J. Van-leeuwen, T. Vermeire, A. Van-nuijs, A. Covaci, H. Beyers et al., Do concentrations of pharmaceuticals in sewage reflect prescription figures?, Springer Science & Business Media, vol.22, pp.9110-9118, 2007.

P. Verlicchi, A. Galletti, M. Petrovic, and D. Barceló, Hospital effluents as a source of emerging pollutants: an overview of micropollutants and sustainable treatment options, J Hydrol, vol.389, pp.416-428, 2010.

P. Verlicchi, A. Aukidy, M. Zambello, and E. , Occurrence of pharmaceutical compounds in urban wastewater: removal, mass load and environmental risk after a secondary treatment-a review, Sci Total Environ, vol.429, pp.123-155, 2012.

J. Zhang, V. Chang, A. Giannis, and J. Y. Wang, Removal of cytostatic drugs from aquatic environment: a review, Sci Total Environ, pp.281-298, 2013.